Please login to the form below

Not currently logged in
Email:
Password:

CLL

This page shows the latest CLL news and features for those working in and with pharma, biotech and healthcare.

Roche keeps Venclexta train rolling with new leukaemia filing

Roche keeps Venclexta train rolling with new leukaemia filing

Venclexta was first approved as a second-line therapy for chronic lymphocytic leukaemia (CLL) patients with a chromosomal abnormality known as 17p deletion in 2016 and – last month – the eligible patient ... population was expanded after the

Latest news

  • AbbVie, Roche get FDA OK for broader use of Venclexta AbbVie, Roche get FDA OK for broader use of Venclexta

    A regimen based on AbbVie/Roche’s Venclexta for chronic lymphocytic leukaemia (CLL) - which has been described as ‘practice-changing’ - has been approved in the US. ... It means that the chemotherapy-free regimen can be used in a much broader

  • AbbVie trial backs chemo-free Imbruvica combo regimen AbbVie trial backs chemo-free Imbruvica combo regimen

    AbbVie trial backs chemo-free Imbruvica combo regimen. Imbruvica paired with Roche’s Gazyva for previously untreated CLL patients. ... or more) with either CLL or small lymphocytic leukaemia (SLL) – a different form of the same disease.

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    The first BTK inhibitor to reach the market was Johnson &Johnson (J&J) and Pharmacyclics' Imbruvica (ibrutinib), but this has been introduced initially for blood cancers including chronic lymphocytic leukaemia (CLL)

  • NICE backs Roche’s Gazyvaro after initial rejection NICE backs Roche’s Gazyvaro after initial rejection

    Previously, NICE also cleared Gazyvaro as a routine NHS treatment option for adults with chronic lymphocytic leukaemia (CLL).

  • AZ gets early FDA green light for Imbruvica challenger AZ gets early FDA green light for Imbruvica challenger

    The drug is being tested in additional indications already held by Imbruvica - including the larger chronic lymphocytic leukaemia (CLL) market and Waldenström’s macroglobulinemia - and AZ is also running a ... to-head comparison of the two drugs in CLL

More from news
Approximately 10 fully matching, plus 79 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Asset acquisition - products. 121. † Eagle Pharmaceuticals/ Teva. EP-3102 - bendamustine hydrochloride rapid infusion product - CLL, indolent B-cell NHL. ... CLL, chronic lymphocytic leukaemia; NHL, indolent non-Hodgkin lymphoma.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Quest Diagnostics / Royalty Pharma. Purchase of royalty rights. Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3). ... Abbreviations. ImmTacs = Immune mobilising mTCR against cancer. CLL = chronic lymphocytic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics